Stock A036480 DAESUNG MICROBIOLOGICAL LABS. CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Daesung Microbiological Labs. Co., Ltd.

Equities

A036480

KR7036480002

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 13/05/2024 BST 		5-day change 1st Jan Change
10,840 KRW +0.93% Intraday chart for Daesung Microbiological Labs. Co., Ltd. -0.73% -1.00%
2023 Daesung Microbiological Labs. Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Daesung Microbiological Labs. Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 66,880 60,420 61,560 54,530 39,140 41,610
Enterprise Value (EV) 1 56,531 59,759 73,410 66,948 48,310 53,894
P/E ratio 21.1 x 24.5 x 40.5 x 63 x 23 x -61.2 x
Yield - - - - - -
Capitalization / Revenue 2.66 x 2.4 x 2.48 x 2.27 x 1.53 x 1.63 x
EV / Revenue 2.25 x 2.38 x 2.96 x 2.79 x 1.89 x 2.11 x
EV / EBITDA 13 x 13.3 x 19 x 23.3 x 20.3 x 24.8 x
EV / FCF 34.7 x -6.72 x -6.11 x -62.9 x -48.4 x -28.9 x
FCF Yield 2.89% -14.9% -16.4% -1.59% -2.06% -3.46%
Price to Book 2.03 x 1.74 x 1.7 x 1.47 x 1.01 x 1.11 x
Nbr of stocks (in thousands) 3,800 3,800 3,800 3,800 3,800 3,800
Reference price 2 17,600 15,900 16,200 14,350 10,300 10,950
Announcement Date 01/03/19 29/02/20 01/03/21 01/03/22 01/03/23 29/02/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 25,097 25,134 24,801 23,997 25,500 25,562
EBITDA 1 4,360 4,490 3,865 2,875 2,378 2,173
EBIT 1 3,409 3,380 1,918 337.1 -327.5 -689
Operating Margin 13.59% 13.45% 7.73% 1.4% -1.28% -2.7%
Earnings before Tax (EBT) 1 3,743 2,813 1,529 842.9 2,261 -1,082
Net income 1 3,170 2,471 1,519 865.9 1,703 -679.7
Net margin 12.63% 9.83% 6.12% 3.61% 6.68% -2.66%
EPS 2 834.2 650.3 399.6 227.9 448.2 -178.9
Free Cash Flow 1 1,631 -8,889 -12,016 -1,065 -997.5 -1,862
FCF margin 6.5% -35.37% -48.45% -4.44% -3.91% -7.29%
FCF Conversion (EBITDA) 37.41% - - - - -
FCF Conversion (Net income) 51.46% - - - - -
Dividend per Share - - - - - -
Announcement Date 01/03/19 29/02/20 01/03/21 01/03/22 01/03/23 29/02/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - 11,850 12,418 9,170 12,284
Net Cash position 1 10,349 661 - - - -
Leverage (Debt/EBITDA) - - 3.066 x 4.319 x 3.856 x 5.653 x
Free Cash Flow 1 1,631 -8,889 -12,016 -1,065 -998 -1,862
ROE (net income / shareholders' equity) 10% 7.3% 4.28% 2.36% 4.49% -1.78%
ROA (Net income/ Total Assets) 5.85% 4.74% 2.12% 0.34% -0.32% -0.67%
Assets 1 54,213 52,122 71,773 256,644 -531,417 102,130
Book Value Per Share 2 8,687 9,136 9,556 9,738 10,220 9,829
Cash Flow per Share 2 1,301 2,172 1,372 1,157 1,014 1,148
Capex 1 423 11,439 14,006 2,968 2,315 1,256
Capex / Sales 1.69% 45.51% 56.47% 12.37% 9.08% 4.91%
Announcement Date 01/03/19 29/02/20 01/03/21 01/03/22 01/03/23 29/02/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Veterinary Drugs

1st Jan change Capi.
DAESUNG MICROBIOLOGICAL LABS. CO., LTD. Stock Daesung Microbiological Labs. Co., Ltd.
-1.00% 30.44M
ZOETIS INC. Stock Zoetis Inc.
-12.21% 79.07B
BLUESTAR ADISSEO COMPANY Stock Bluestar Adisseo Company
+25.25% 3.72B
VIRBAC Stock Virbac
+1.39% 3.33B
VIMIAN GROUP AB Stock Vimian Group AB
+17.06% 1.71B
JINYU BIO-TECHNOLOGY CO., LTD. Stock Jinyu Bio-technology Co., Ltd.
-8.73% 1.52B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. Stock China Animal Husbandry Industry Co., Ltd.
-23.19% 1.29B
VETOQUINOL SA Stock Vetoquinol SA
-3.22% 1.29B
WUHAN KEQIAN BIOLOGY CO.,LTD Stock Wuhan Keqian Biology Co.,Ltd
-12.66% 1.15B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD. Stock Tianjin Ringpu Bio-Technology Co.,Ltd.
+0.24% 1.05B
Veterinary Drugs
  1. Stock Market
  2. Equities
  3. A036480 Stock
  4. Financials Daesung Microbiological Labs. Co., Ltd.